Immunologic Factor – Page 5

GSK set to receive over $500M from mRNA patent settlement tied to BioNTech–CureVac–Pfizer deal

1 month ago talkbio0Tagged BioNTech, BioNTech acquisition, COVID19 (disease), CureVac, global framework, Influenza virus vaccine, Licensing, Litigation, Pfizer, RNA, Messenger, royalties, settlement, SmithKline Beecham, U.S., upfront payment, Vaccines, Vaccines, Combined

GSK; CureVac; BioNTech; Pfizer; mRNA patents; settlement; royalties; COVID-19 vaccine; influenza vaccine; combination vaccines; licensing; upfront payment; US litigation; global framework; BioNTech acquisition of CureVac

AbbVie and Genmab Move to Expand Use of T Cell Engager Epkinly Following Strong Phase III Results

1 month ago talkbio0Tagged AbbVie, Antibodies, Bispecific, Approved, Epcoritamab, EPKINLY, expansion, Genmab, Labels (device), lenalidomide, Lymphoma, Follicular, Phase 3 Clinical Trials, rituximab, T-Cell engager, United States Food and Drug Administration

Epkinly; epcoritamab; AbbVie; Genmab; follicular lymphoma; T cell engager; bispecific antibody; Phase III trial; FDA approval; label expansion; Rituximab; Lenalidomide

Strand Therapeutics Raises $153M Series B to Advance mRNA Tumor Drugs

1 month ago talkbio0Tagged Big Pharma investors, biotech financing, Clinical Trials, Genomic Orientation, interleukin-12, mRNA cancer, Series B funding, Solid Neoplasm, STX-001

Strand Therapeutics; Series B funding; mRNA cancer therapy; STX-001; IL-12; solid tumors; Big Pharma investors; clinical trial results; biotech financing

HHS Ends BARDA Funding for Future mRNA Vaccine Development, Citing Efficacy Concerns

1 month ago talkbio0Tagged BARDA, CHARGE Syndrome, COVID19 (disease), Effectiveness, Influenza, mRNA Vaccines, project cancellation, public health policy, Robert F. Kennedy, Vaccines

mRNA vaccines; BARDA; Robert F. Kennedy Jr.; vaccine efficacy; HHS; COVID-19; flu; project cancellation; public health policy

HHS Cancels $500 Million in BARDA-Funded mRNA Vaccine Contracts Amid Strategic Shift

1 month ago talkbio0Tagged BARDA, CHARGE Syndrome, contract cancellation, COVID19 (disease), development aspects, federal funding, Moderna, mRNA Vaccine, Pfizer, Robert F. Kennedy Jr., Seqirus, Vaccines

HHS; BARDA; mRNA vaccine; vaccine development; contract cancellation; Robert F. Kennedy Jr.; COVID-19; federal funding; Moderna; Pfizer; Seqirus

Y-mAbs Therapeutics Acquired by SERB Pharmaceuticals in $412 Million Buyout Following Strategic Review

1 month ago talkbio0Tagged all-cash tender, Danyelza, Infrequent, Merger, Neoplasms, pharmaceutical acquisition, Serbs, strategic review, Y-mAbs

Y-mAbs Therapeutics; SERB Pharmaceuticals; buyout; Danyelza; rare oncology; merger; pharmaceutical acquisition; strategic review; all-cash tender offer

Imunon Halts COVID-19 Vaccine Program, Seeks Partner Due to Financial Struggles

1 month ago talkbio0Tagged Cash Crunch, COVID19 (disease), deprioritization, financial results, IMNN-101, Imunon, Partnership, Vaccines

Imunon; COVID-19 vaccine; IMNN-101; deprioritization; cash crunch; partnership; financial results

Replimune Awaits FDA Direction After Complete Response Letter for Advanced Melanoma Therapy

1 month ago talkbio0Tagged Accelerated, Advanced Melanoma, Approved, Cancer Therapeutic Procedure, Complete, IGNYTE trial, nivolumab, Replimune, Response Letter, RETINITIS PIGMENTOSA 1, United States Food and Drug Administration, vusolimogene oderparepvec

Replimune; FDA; Complete Response Letter; RP1; vusolimogene oderparepvec; nivolumab; advanced melanoma; cancer treatment; IGNYTE trial; accelerated approval

Allogene Reports Patient Death Linked to ALLO-647 Conditioning Antibody in CAR-T Trial

1 month ago talkbio0Tagged Adenovirus Infections, Allogene, ALPHA3 trial, Anti-CD52 Monoclonal Antibody ALLO-647, CAR-T, Liver Failure, Lymphodepletion Therapy, Monoclonal Antibodies, Patient Death

Allogene; ALLO-647; CAR-T; patient death; monoclonal antibody; lymphodepletion; large B-cell lymphoma; ALPHA3 trial; liver failure; adenovirus infection

Moderna Wins UK Appeals Court in Covid-19 Patent Case Against Pfizer/BioNTech

1 month ago talkbio0Tagged appeal, BioNTech, court, COVID19 (disease), EP'949, infringement, Legal patent, legal victory, Moderna, Pfizer, UK, Vaccines

Moderna; Pfizer; BioNTech; UK Court of Appeal; COVID-19 vaccine; patent infringement; EP’949 patent; Comirnaty; legal victory